December 16, 2021 – Spanish pharmaceutical company Ferrer and the Spanish National Center for Cardiovascular Research (Centro Nacional de Investigaciones Cardiovasculares — CNIC), announced the results of NEPTUNO, the first real-world clinical study on patients treated with the CNIC-Polypill. This single pill, composed of the three class A medications recommended in the cardiovascular prevention guidelines,[1] is used to treat patients who have previously suffered a cardiovascular (CV) event, such as heart-attack or ischemic stroke.
Â
